Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
Allergy2021Vol. 76(9), pp. 2840–2854
Citations Over TimeTop 10% of 2021 papers
Musa Khaitov, Alexandra Nikonova, I.P. Shilovskiy, Ksenia V. Kozhikhova, И.А. Кофиади, Lyudmila Vishnyakova, А. А. Никольский, Pia Gattinger, V.I. Kovchina, Ekaterina Barvinskaia, Kirill Yumashev, Valeriy Smirnov, Artem Maerle, I.B. Kozlov, Artem Shatilov, Anastasiia V. Timofeeva, Sergey Andreev, О. О. Колоскова, Nadezhda A. Kuznetsova, Daria V. Vasina, Maria A. Nikiforova, Sergei D. Rybalkin, I.V. Sergeev, D. Yu. Trofimov, Alexander Martynov, Igor Berzin, Vladimir А. Gushchin, A. O. Kovalchuk, Sergei V. Borisevich, Rudolf Valenta, Rakhim M. Khaitov, В. В. Скворцова
Abstract
Thus, we developed a therapeutic strategy for COVID-19 based on inhalation of a modified siRNA-peptide dendrimer formulation. The developed medication is intended for inhalation treatment of COVID-19 patients.
Related Papers
- → SID-I is implicated in systemic gene silencing in the honey bee(2006)102 cited
- → Normalization of Overexpressed α-Synuclein Causing Parkinson's Disease By a Moderate Gene Silencing With RNA Interference(2015)77 cited
- → Can siRNA Technology Provide the Tools for Gene Therapy of the Future?(2006)34 cited
- → <i>In vivo</i> siRNA Delivery to Tumor Cells and Its Application to Cancer Gene Therapy(2007)5 cited
- → Death without stress: The stiletto approach against disease(2004)3 cited